**To the editor:** While statins have been clearly shown to decrease mortality and morbidity in cardiovascular diseases, the role of statins as an anti-cancer agent is less well defined. Predicted through new guidelines published by American College of Cardiology, it is said that around 30% of Americans in the age group 40 to 75 will be using statins even if they do not have cardiovascular disease \[[@B1]\]. Recently, statin\'s beneficial effect on cancer survival has also been highlighted in many studies. A Danish study \[[@B2]\] reported that people who have used statins have 20% lower chance of cancer deaths compared with those who have not used statins. Similarly studies have also shown that statins lower the incidence of common cancers such as breast, prostate and colorectal. This anticancer activity of statins is due to inhibition of isoprenoid biosynthesis which is essential for cancer growth and metastasis \[[@B3][@B4]\].

Ovarian cancer has the worst prognosis among gynecological cancers. It has been estimated that ovarian cancer causes approximately 15,000 deaths in USA annually \[[@B5]\]. Therefore, identification of protective factors and possible agents associated with increased survival can have great implications. Statin\'s role in ovarian cancer has been controversial with varying opinions. In order to collect all the evidence, we conducted a literature search utilizing Medline (PubMed and Ovid) and Cochrane Library to identify studies related to statins effect on incidence and survival in ovarian cancer. Eight relevant citations were found and are summarized in [Table 1](#T1){ref-type="table"}. Only three studies \[[@B6][@B7][@B8]\] were found which reported the effect of statin therapy on ovarian cancer survival while the others \[[@B9][@B10][@B11][@B12][@B13]\] only reported risk of ovarian cancer.

Habis et al. \[[@B6]\] reported a decrease in hazards of disease-specific death (adjusted hazard ratio, 0.23; p=0.04) among statin users in non-serous papillary epithelial ovarian cancer. Similarly Elmore et al. \[[@B7]\] showed significantly longer survival in statin users (62 months) compared with non-users (46 months, p=0.04). Out of the six studies \[[@B8][@B9][@B10][@B11][@B12][@B13]\] reporting risk of ovarian cancer, only one found a significant reduction in ovarian cancer incidence with statin usage. Baandrup et al. \[[@B9]\] documented a decrease risk only with respect to mucinous ovarian cancer enforcing the need for further subgroup analysis.

When findings of five studies \[[@B8][@B10][@B11][@B12][@B13]\] were pooled in a meta-analysis conducted by Liu et al. \[[@B14]\], a significant 21% risk reduction was seen (relative risk \[RR\], 0.79; 95% confidence interval \[CI\], 0.64 to 0.98). The RR reduction was found to be 52% when long term statin usage was considered (RR, 0.48; 95% CI, 0.28 to 0.80). In conclusion, we suggest that statins impact on ovarian cancer warrants further investigation with larger randomized controlled trials as observational studies are subject to bias and may lead to false slight benefits. Effect of statins with respect to different histological subtypes also need to be further studied.
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###### Summary of the evidence regarding impact of statin therapy on risk and survival of ovarian cancer
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  Study                                 Type of study                 Size of population                       Primary outcome variable                                  Conclusion
  ------------------------------------- ----------------------------- ---------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Habis et al. (2014) \[[@B6]\]         Retrospective cohort          442                                      Progression-free survival and disease-specific survival   Improved survival among statin users was not seen except in non-serous papillary epithelial ovarian cancer
  Elmore et al. (2008) \[[@B7]\]        Retrospective cohort          126                                      Progression-free survival and overall survival            Improved survival was seen in statin users
  Lavie et al. (2013) \[[@B8]\]         Case control study            Cases, 12; matched controls, 126         Risk of ovarian cancer and survival                       Decreased risk along with improved survival was reported
  Baandrup et al. (2015) \[[@B9]\]      Case control study            Cases, 4,103; matched controls, 58,706   Risk of epithelial ovarian cancer                         Decreased risk seen in mucinous ovarian cancer. No association with epithelial subtype
  Yu et al. (2009) \[[@B10]\]           Retrospective cohort          73,336                                   Risk of ovarian cancer                                    Non-significant decrease in ovarian cancer risk was found
  Kaye et al. (2004) \[[@B11]\]         Case control study            Cases, 91; controls, 7,393               Risk of ovarian cancer                                    Statins have no substantial effect on ovarian cancer risk
  Friedman et al. (2008) \[[@B12]\]     Retrospective cohort          361,859                                  Risk of ovarian cancer                                    No association was found
  Clearfield et al. (2001) \[[@B13]\]   Randomized controlled trial   997                                      Risk of ovarian cancer                                    No difference in frequency of cancer between statin users/non-users was reported
